NSTEMI: Elderly patients ‘benefit from invasive treatment’
Invasive treatment gives patients 80 years and older with non-ST elevation myocardial infarction (NSTEMI) a five-year survival advantage along with fewer admissions for heart failure, a UK study suggests.
Researchers examined data on 1500 patients 80 years and older who had troponin measurements and were diagnosed with NSTEMI from 2010-17.
Patients in the study had a median age of 86 years, and 56% received non-invasive management for NSTEMI. During a median follow-up of three years, 41% died.
The adjusted cumulative five-year mortality was 36% with invasive management and 55% with non-invasive management, showing a 32% reduction in mortality with invasive management, the authors reported in The Lancet.